News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Sponsor & Foundation News

Acorda Announces FDA Acceptance of New Drug Application for INBRIJA™

Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis from EASE LID 2 Open-label Study

Sunovion Announces Positive Results from Study of Apomorphine Sublingual Film in Patients with PD

Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA Approved Medication for the Treatment of Dyskinesia in Parkinson's Disease Patients

Boston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation System

Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija

Acorda Resubmits New Drug Application for INBRIJA™ (CVT-301, levodopa inhalation powder)

Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced PD

Voyager’s AADC Gene Therapy Shows Promise as Maintenance Therapy for Parkinson’s Disease

GOCOVRI for Dyskinesia Gets Orphan Drug Designation

Distinguished Movement Disorders Researchers to Lead Fresco Institute at NYU Langone Health

New Phase 3 Trial to Test Nuplazid for Parkinson’s Psychosis in Array of Dementia Patients

Voyager Therapeutics Presents Promising Parkinson’s Data

Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

The Michael J. Fox Foundation Announces Award to Drive Phase IIa Clinical Trial Investigating Potential Safety and Benefit of Nilotinib in PD

Forbes Includes Acadia, Maker of Nuplazid on List of Most Innovative Growth Companies

Mitsubishi Buys Israel's NeuroDerm for $1.1B

Participants Invited to Take Survey on Vision and Parkinson’s Disease

US WorldMeds is Now Distributing XADAGO® (Safinamide) in the U.S. for PD Patients

Acorda Submits New Drug Application to U.S. Food and Drug Administration for CVT-301

Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study

NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders

Acorda Therapeutics to Present Update on Phase 3 Study of CVT-301 in Parkinson’s Patients

Survey Examines Social Support in Parkinson’s Disease from the Patient’s Perspective

UCB Adds Website for its Facebook-based Parkinson's Community

Acorda Expands Alexa Skill Offering for Parkinson’s Awareness Month

Acorda Announces Long-Term Safety Data for CVT-301

FDA Approves Xadago to Treat Parkinson’s Disease

US WorldMeds is Funding Clinical Trial Studying Effectiveness of New Infusion Therapy to Help Smooth Out Movement for Patients with PD

Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301

LSVT BIG Seminar on Sunday, February 5, 2017 in West Orange, NJ

The Parkinson’s Institute and Clinical Center Awarded $1.9 Million from California Institute for Regenerative Medicine

back to top